<DOC>
	<DOCNO>NCT00521950</DOCNO>
	<brief_summary>The purpose study determine whether thiopurine S-methyltransferase ( TPMT ) genotyping prior thiopurine use cost-effective patient inflammatory bowel disease ( IBD ) need immune suppression . The study design test hypothesis optimization initial thiopurine dose base pre-treatment TPMT genotyping maximize treatment efficacy minimize adverse drug reaction ( ADRs ) result reduce cost .</brief_summary>
	<brief_title>Cost-effectiveness TPMT Pharmacogenetics</brief_title>
	<detailed_description>Immunosuppressives , e.g . azathioprine ( AZA ) 6-mercaptopurine ( 6-MP ) , important induction remission long term treatment ( ulcerative ) colitis Crohn 's disease treatment 5-aminosalicylates corticosteroid fails . ADRs immunosuppressive treatment , include myelosuppression hepatotoxicity , frequently ( 15-30 % ) observe . Genetic variation TPMT gene result 10-11 % general population reduce 0.3-0.6 % negligible TPMT enzyme activity . In IBD patient , genetic variation predict 25-40 % haematological ADRs necessitate temper thiopurine dose discontinuation treatment . Pharmacogenetics aim provide optimize drug treatment patient maximize efficacy minimize adverse drug reaction ( ADRs ) base genetic testing . Despite proven value pharmacogenetics clinical practice , use medical care still limit . The best-established example pharmacogenetic test genotyping thiopurine S-methyltransferase ( TPMT ) treatment patient immunosuppressive thiopurines . Nonetheless , use large scale clinical practice far , might due : insufficient information transfer research clinic ; lack cost-effectiveness analysis ( CEAs ) ; lack availability ( access ) fast and/or cheap genotyping ; lack test reimbursement health insurance .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<criteria>Age 18 old Diagnosis form IBD Indication azathioprine/6MP treatment Patient give ( write ) inform consent Previous treatment azathioprine/6MP Coprescription allopurinol ( treatment block xanthine oxidase , enzyme important thiopurine metabolism ) Baseline leukocyte count le 3x10^9 per litre Reduced liver function baseline Reduced renal function baseline Known TPMT phenotype ( enzyme activity / Therapeutic Drug Monitoring ) genotype Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Cost Effectiveness</keyword>
	<keyword>Inflammatory Bowel Diseases</keyword>
	<keyword>Crohn Disease</keyword>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Randomized Controlled Trials</keyword>
</DOC>